COMP360 (psilocybin therapy)
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
investigational drug
psilocybin formulation |
| gptkbp:activeIngredient |
psilocybin
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:countryOfOrigin |
gptkb:United_Kingdom
|
| gptkbp:developedBy |
gptkb:COMPASS_Pathways
|
| gptkbp:form |
oral capsule
|
| gptkbp:headquartersLocation |
gptkb:London
|
| https://www.w3.org/2000/01/rdf-schema#label |
COMP360 (psilocybin therapy)
|
| gptkbp:intendedUse |
treatment-resistant depression
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
serotonin receptor agonist
|
| gptkbp:regulates |
gptkb:Breakthrough_Therapy_Designation
|
| gptkbp:relatedTo |
psychedelic therapy
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:studiedIndication |
gptkb:major_depressive_disorder
treatment-resistant depression |
| gptkbp:trialIdentifier |
gptkb:NCT03775200
gptkb:NCT04052568 gptkb:NCT05149502 |
| gptkbp:trialSponsor |
gptkb:COMPASS_Pathways
|
| gptkbp:bfsParent |
gptkb:COMPASS_Pathways
|
| gptkbp:bfsLayer |
7
|